CHICAGO -- September 30, 2015 -- Ozanezumab, a monoclonal antibody, has demonstrated disappointing efficacy results against the neurite outgrowth inhibitor protein Nogo-A in patients with amyotrophic lateral sclerosis (ALS), according to results of a phase 2 study presented at the 140th Annual Meeting of the American Neurological Association (ANA).
The Neurology Spectrum
Check this site frequently for recent updates in Neurology!
Click the RSS feed for continual updates! Contact us to be placed on the mailing list and receive updates directly to your email!